1. Home
  2. JZ vs NCEL Comparison

JZ vs NCEL Comparison

Compare JZ & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jianzhi Education Technology Group Company Limited

JZ

Jianzhi Education Technology Group Company Limited

HOLD

Current Price

$0.17

Market Cap

17.7M

Sector

Real Estate

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

N/A

Current Price

$3.40

Market Cap

17.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JZ
NCEL
Founded
2011
2008
Country
China
Switzerland
Employees
N/A
4
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.7M
17.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
JZ
NCEL
Price
$0.17
$3.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.7M
30.5K
Earning Date
04-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$1.83
52 Week High
$3.35
$5.12

Technical Indicators

Market Signals
Indicator
JZ
NCEL
Relative Strength Index (RSI) 42.19 57.62
Support Level N/A $2.95
Resistance Level $1.04 $3.62
Average True Range (ATR) 0.07 0.25
MACD -0.03 0.02
Stochastic Oscillator 0.72 88.61

Price Performance

Historical Comparison
JZ
NCEL

About JZ Jianzhi Education Technology Group Company Limited

Jianzhi Education Technology Group Co Ltd engages in developing educational content to fulfill the massive demand for high-quality, professional development training resources in China. The company and its subsidiaries VIE and VIEs generate subscription revenue through selling subscriptions to online learning platforms, higher education institutions, and other institutional customers under a B2B2C model mainly through the platform of Sentu Academy; offering subscriptions concerning educational content in mobile video packages directly to end users under a B2C model through the platforms such as Fish Learning or Light Class, etc. It has single operating segment: Educational content services and other services and IT-related solution services.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: